Opinion: Ethically Accessing Experimental Therapies for COVID-19

In the midst of a pandemic, individual patients are not always the focus of the ethics discussions.

| 4 min read

Listen with Speechify

0:00

4:00

ABOVE: © ISTOCK.COM, SUDOK1

Normally, it takes about eight years to move a drug through clinical trials and approval by the US Food and Drug Administration. In the current pandemic, patients don’t have this time to wait for COVID-19 therapies. How can we responsibly speed innovation, access to experimental medicines, and FDA approvals during this public health emergency?

There is no shortage of calls to act more quickly in response to this pandemic. Mike Ryan, the executive director of the health emergencies program at the World Health Organization (WHO), for example, urged everyone at a press conference this week: “Be fast. Have no regrets. . . . The virus will always get you if you don’t move quickly. . . . If you need to be right before you move, you will never win. . . . Everyone is afraid of the consequence of error. But the greatest error is ...

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member? Login Here

Keywords

Meet the Author

John D. Loike
John Loike serves as the interim director of bioethics at New York Medical College and as a professor of biology at Touro University. His biomedical research focuses on how human white blood cells combat infections and cancer.
View full profile
Jennifer E. Miller
This person does not yet have a bio.
View full profile